LETERMOVIR 240 MG TABLETS
PREVYMIS (letermovir) contains letermovir, an inhibitor of the CMV DNA terminase complex, and is administered orally or by intravenous infusio. PREVYMIS is available as 240 mg and 480 mg tablets. PREVYMIS tablets contain either 240 mg or 480 mg of letermovir and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone 25, and film-coated with a coating material containing the following inactive ingredients: hypromellose 2910, iron oxide red (only for 480 mg tablets), iron oxide yellow, lactose monohydrate, titanium dioxide, and triacetin, Carnauba wax is added as a polishing agent.
"PREVYMIS (letermovir) - Tablet: 240 mg; 480 mg.
Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL)
in a single-dose vial. "
The recommended dosage is 480 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-transplant. Dosage Adjustment: if PREVYMIS is co-administered with cyclosporine, the dosage of PREVYMIS should be decreased to 240 mg once daily
PREVYMIS (letermovir) is a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT
